IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

1999-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

NCT00632216

Osteoporosis, Postmenopausal

COMPLETED PHASE4

Satisfaction and Compliance of Risedronate in PMO

NCT00549965

Osteoporosis, Postmenopausal

COMPLETED PHASE4

Risedronate Sodium in Post Menopausal Osteoporosis

NCT00453492

Osteoporosis, Postmenopausal

COMPLETED PHASE4

Risedronate in Postmenopausal Women With Low Bone Density

NCT00351091

OSTEOPOROSIS, POSTMENOPAUSAL

COMPLETED PHASE2

Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover

NCT01249261

Postmenopausal Women With Osteoporosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

risedronate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory women,
* Caucasian, Oriental or Multiracial
* not previously diagnosed for osteoporosis.

Exclusion Criteria

* Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis
* and having used oral or parenteral glucocorticoids (\>= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

65 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No